Evaluation of a Capped Dosing Telavancin Regimen Compared to Standard Dosing at a Large Community Teaching Hospital-Reference-Cited by-同舟云学术

Evaluation of a Capped Dosing Telavancin Regimen Compared to Standard Dosing at a Large Community Teaching Hospital

Published:2022-01-18 Issue:1 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Diggs Fernando J.¹,Edwards Jonathan D.¹,Garza Kimberly B.²,Hassoun Ali A. M.³,Durham Spencer H.⁴^ORCID

Affiliation:

1. Department of Pharmacy, Huntsville Hospital, Huntsville, Alabama, USA

2. Department of Health Outcomes Research and Policy, Auburn University Harrison School of Pharmacy, Auburn, Alabama, USA

3. Department of Infectious Diseases, Huntsville Hospital, Huntsville, Alabama, USA

4. Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Auburn, Alabama, USA

Abstract

Telavancin, a lipoglycopeptide antibiotic, is traditionally dosed at 10 mg/kg based on total body weight but is associated with toxicities that limit its use. This study supports the use of a capped dosing regimen of 750 mg in obese patients, which is associated with equal efficacy and fewer adverse effects compared to traditional dosing.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01603-21

Reference10 articles.

1. Telavancin: A Novel Lipoglycopeptide Antibiotic

2. Cumberland Pharmaceuticals Inc. July 2020. Vibativ package insert. Cumberland Pharmaceuticals Inc. Nashville TN.

3. Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms

4. Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

5. Acute renal insufficiency during telavancin therapy in clinical practice